95 related articles for article (PubMed ID: 15068000)
21. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
22. Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy.
Zhang FK; Zhang Y; Zhang JY; Jia JD; Wang BE
Transpl Infect Dis; 2009 Dec; 11(6):549-52. PubMed ID: 19725909
[TBL] [Abstract][Full Text] [Related]
23. Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
Thio CL
J Hepatol; 2006 Jan; 44(1):1-3. PubMed ID: 16293338
[No Abstract] [Full Text] [Related]
24. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
Ikeda F; Baba N; Takaguchi K; Kubota J; Miyoshi K; Fujioka S; Moritou Y; Takeuchi Y; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K
J Med Virol; 2012 Oct; 84(10):1562-70. PubMed ID: 22930504
[TBL] [Abstract][Full Text] [Related]
26. Antiviral options for the treatment of chronic hepatitis B.
Osborn MK; Lok AS
J Antimicrob Chemother; 2006 Jun; 57(6):1030-4. PubMed ID: 16595637
[TBL] [Abstract][Full Text] [Related]
27. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B and human immunodeficiency virus coinfection.
Thio CL
Hepatology; 2009 May; 49(5 Suppl):S138-45. PubMed ID: 19399813
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
30. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
31. Adefovir dipivoxil in the treatment of chronic hepatitis B.
Rivkin AM
Ann Pharmacother; 2004 Apr; 38(4):625-33. PubMed ID: 14990784
[TBL] [Abstract][Full Text] [Related]
32. Low-dose adefovir for the treatment of chronic hepatitis B in HIV-infected people.
Brust DG
GMHC Treat Issues; 2001; 15(11-12):8-11. PubMed ID: 11819970
[No Abstract] [Full Text] [Related]
33. [The first nucleotide analog permitted. New hepatitis B therapy helps the problem patients, too].
MMW Fortschr Med; 2003 Jun; 145(24):52. PubMed ID: 12866303
[No Abstract] [Full Text] [Related]
34. Rapid improvement of liver function in a patient with HIV and hepatitis B coinfection treated with lamivudine and tenofovir.
Lehmann C; Wyen C; Fätkenheuer G
Infection; 2006 Aug; 34(4):234-5. PubMed ID: 16896585
[TBL] [Abstract][Full Text] [Related]
35. Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy?
Zoulim F
Hepatology; 2003 Dec; 38(6):1353-5. PubMed ID: 14647043
[No Abstract] [Full Text] [Related]
36. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
37. Update on the management of chronic hepatitis B.
Davis GL
Rev Gastroenterol Disord; 2002; 2(3):106-15. PubMed ID: 12227214
[TBL] [Abstract][Full Text] [Related]
38. Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.
Rodriguez-Frias F; Jardi R; Schaper M; Buti M; Ferrer-Costa C; Tabernero D; Homs M; Esteban R
Antivir Ther; 2008; 13(8):991-9. PubMed ID: 19195324
[TBL] [Abstract][Full Text] [Related]
39. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
